{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T15:48:54Z","timestamp":1781452134999,"version":"3.54.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>As a programmed cell death 1 (PD-1) inhibitor, camrelizumab is used in the treatment of a variety of malignancies. However, a variety of immune-mediated adverse reactions have been reported in a wide range of clinical applications, including immune-related colitis, arthritis, hepatitis, etc.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>This 56-year-old male patient experienced diarrhea, bloody stool, and knee pain after receiving camrelizumab for metastatic esophageal squamous cell carcinoma. Colonoscopy showed granular changes in the whole colonic mucosa and blurred or even disappeared vascular texture. Pathology showed chronic inflammation of the colonic mucosa. Magnetic resonance imaging of knee joint showed exudative inflammatory changes in bilateral knee joints.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Immune checkpoint inhibitor-induced colitis and arthritis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Mesalazine oral (extended-release granules, 1000\u2009mg\/quarter in die daily). Dexamethasone sodium phosphate (once daily, 5mg in the evening) and compound cypress liquid (once daily, 100ml in the evening) were given by enema. Anti-inflammatory and analgesic treatment of bone pain plaster.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient had diarrhea reduced to 3 times\/day, no more bloody stools, and the knee pain was relieved.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This article describes the cases of immune-related colitis and arthritis caused by camrelizumab, and recommends considering the risk of colitis and arthritis with camrelizumab monotherapy or combination therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000036334","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T17:02:53Z","timestamp":1708534973000},"page":"e36334","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Immune checkpoint inhibitor induced colitis and arthritis: A case report"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7056-5924","authenticated-orcid":false,"given":"Rong-Xin","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Bao","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong First Medical University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yu","family":"Ci","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0730-996X","authenticated-orcid":false,"given":"Mei-Juan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Health Management, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering Laboratory for Health Management, Jinan, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/s12903-021-01901-9","article-title":"Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review.","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Oral Health"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1158\/1078-0432.CCR-19-3922","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial.","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"768957","DOI":"10.3389\/fimmu.2021.768957","article-title":"Mechanisms of immune checkpoint inhibitor-mediated colitis.","volume":"12","author":"Westdorp","year":"2021","journal-title":"Front Immunol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: first global approval.","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1634\/theoncologist.2016-0390","article-title":"Inflammatory arthritis: a newly recognized adverse event of immune checkpoint blockade.","volume":"22","author":"Naidoo","year":"2017","journal-title":"Oncologist"},{"key":"R7-20250503","article-title":"Progress in immune checkpoint inhibitors and their associated colitis.","volume":"25","author":"Zheng","year":"2020","journal-title":"Gastroenterology"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"E1598","DOI":"10.1002\/ibd.21927","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis?","volume":"18","author":"Nancey","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12876-018-0864-1","article-title":"The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review.","volume":"18","author":"Yamauchi","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab.","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11523-017-0495-4","article-title":"Immune checkpoint inhibitor-induced colitis: diagnosis and management.","volume":"12","author":"Prieux-Klotz","year":"2017","journal-title":"Targeted Oncol"},{"key":"R12-20250503","first-page":"480","article-title":"Vedolizumab attenuates immune-checkpoint-therapy-induced infliximab-refractory colitis.","volume":"12","author":"Kaneoka","year":"2022","journal-title":"Diagnostics (Basel, Switzerland)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:26:19Z","timestamp":1746318379000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":12,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036334","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]}}}